The AI Protein Design market presents a strong growth narrative, driven by rising demand for therapeutics and biomanufacturing. Market attractiveness is high, underpinned by multi‑billion revenue potential and tailwinds from genomics, cloud computing, and venture capital inflows. Competitive intensity remains moderate; a few startups and biotech giants dominate, yet barriers to entry rise as data‑centric platforms require proprietary datasets and specialized talent. Long‑term outlook is positive, with CAGR projections above 30% through 2035, reflecting expanding use cases in antibody engineering, enzyme optimization, and novel food proteins. The innovation landscape is active, highlighted by breakthroughs in generative modeling, reinforcement learning for fold prediction, and hybrid workflows that shorten design cycles from months to weeks. Demand–supply balance tilts toward demand, as pharmaceutical pipelines accelerate faster than the supply of validated AI models and skilled computational biologists. Key risk factors include data privacy regulations, model interpretability challenges, and potential market consolidation that could limit collaborative ecosystems. This AI Protein Design market outlook underscores the strategic importance of early investment and partnership to capture emerging value.